Maj-Britt Kaltoft
Corporate Officer/Principal chez Statens Serum Institute
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Sylvie Grégoire | M | 62 | 9 ans | |
Poul Rødbroe Rasmussen | M | - |
Statens Serum Institute
| - |
Mette Agger | F | 59 |
Statens Serum Institute
| - |
Niels Borregaard | M | 73 |
University of Copenhagen
| 26 ans |
Doug Langa | M | 58 | 13 ans | |
Stephen Gough | M | - | 9 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Christer Rosén | M | 72 |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | 13 ans |
Laura Spalding | F | - |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | - |
Mats Gunnar Pettersson | M | 78 | 10 ans | |
Henrik Ramlau-Hansen | M | 67 |
University of Copenhagen
| 9 ans |
Kåre Schultz | M | 62 |
University of Copenhagen
| 28 ans |
Kim Vilbour Andersen | M | - |
University of Copenhagen
| 5 ans |
Jacob Tolstrup | M | 52 | 25 ans | |
Jacob Uittenbogaard | M | - |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | - |
Nikolai Søren Kirkby | M | - |
University of Copenhagen
| 4 ans |
Jesper Nerlov | M | 56 |
University of Copenhagen
| 8 ans |
Lykke Friis | M | 54 |
University of Copenhagen
| 10 ans |
Ana de Jesus-Johansson | F | - |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | - |
Jørn Møller Mayntzhusen | M | 58 | - | |
Jesper Parnevik | M | - |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | 13 ans |
Lars Christian Lassen | M | - | - | |
Jakob Riis | M | 58 |
University of Copenhagen
| 5 ans |
Martin Jensen | M | 64 |
University of Copenhagen
| 10 ans |
Anne Prener | M | 66 | 12 ans | |
Jesper Alling Coverdale Kofoed | M | - |
University of Copenhagen
| 7 ans |
Bratanata Perdana | M | 55 |
Seattle University
| 5 ans |
Soren Mogelsvang | M | 52 |
University of Copenhagen
| 6 ans |
Thomas Price | M | 68 | 1 ans | |
Peter Henrik Kürstein-Jensen | M | 68 | 11 ans | |
Peter Andersen | M | 67 | - | |
Liz Hewitt | F | 67 | 9 ans | |
Eva Steiness | M | 83 | 9 ans | |
Helge Lund | M | 61 | 1 ans | |
Sten Scheibye | M | 72 | 10 ans | |
Lise Kingo | F | 62 | 26 ans | |
Anders Gersel Pedersen | M | 73 | 18 ans | |
Claus Tycho Bræstrup | M | 79 | 10 ans | |
Kurt Anker Nielsen | M | 78 | 13 ans | |
Alan Rubino | M | 69 | 18 ans | |
Mary Szela | F | 60 | 3 ans | |
Hannu Ragnvald Ryöppönen | M | 72 | 6 ans | |
Thomas Dywremose | M | - |
University of Copenhagen
| 6 ans |
Thomas Paul Koestler | M | 72 | 5 ans | |
Bruno Francois Jules Angelici | M | 77 | 6 ans | |
Jeppe Fonager Christiansen | M | 64 |
University of Copenhagen
| 1 ans |
Claus Steensen Sølje | M | 52 |
University of Copenhagen
| 1 ans |
Jacob Hübertz | M | - |
University of Copenhagen
| 6 ans |
Jan Fuhr Miller | M | 54 | 11 ans | |
Mikkel Dyhr Gadegaard | M | 45 | 4 ans | |
Johan Kirstein Brammer | M | 48 |
University of Copenhagen
| 3 ans |
Philip Christiani | M | - |
University of Copenhagen
| 6 ans |
Pamela Kirby | M | 70 | 3 ans | |
Christoffer Erik Lorenzen | M | 48 | 5 ans | |
Bradley Patricia | F | - | 2 ans | |
Lida Skifte Lennert | F | 52 |
University of Copenhagen
| - |
Karen Lauberg Lauritsen | F | 56 | 12 ans | |
Michael Moyell Juul | M | 50 |
University of Copenhagen
| 4 ans |
Jes Trygved | M | 51 | 3 ans | |
Jakob Poulsen | M | - |
University of Copenhagen
| 6 ans |
Morten Weicher Weicher | M | - |
University of Copenhagen
| - |
Eivind Kolding | M | 64 | - | |
Jan Hoff | M | - | - | |
Krisja Vermeylen | F | 62 | 3 ans | |
Christian Bornfeld | M | 47 |
University of Copenhagen
| 1 ans |
Joan Schmidt | F | 60 | 20 ans | |
Claus S. Kallesoe | M | - | 14 ans | |
Christian Vinding Thomsen | M | - |
University of Copenhagen
| 3 ans |
Mozhgan Dorkhan | M | 54 | 6 ans | |
Atilla Olesen | M | - |
University of Copenhagen
| 6 ans |
henrik Danielsen | M | - |
University of Copenhagen
| 6 ans |
Per Toft Valstorp | M | 75 | 14 ans | |
Jørgen Nergaard Gøl | M | - |
University of Copenhagen
| 4 ans |
Alexander U. Conrad | M | 53 |
Seattle University
| 2 ans |
Casper Bych | M | 52 |
University of Copenhagen
| 3 ans |
Martin Lauge Bek-Nielsen | M | 49 |
University of Copenhagen
| 4 ans |
Hans Henrik Munch-Jensen | M | 64 | 8 ans | |
John P. Slonecker | M | - |
Seattle University
| 4 ans |
Nils Aage Brünner | M | 72 |
University of Copenhagen
| 12 ans |
Louis Illum Honoré | M | 62 |
University of Copenhagen
| 4 ans |
Ulrik Carstens | M | - |
University of Copenhagen
| 6 ans |
Thomas Dyrberg | M | 69 |
University of Copenhagen
| 3 ans |
Lisbeth Hald | F | - |
University of Copenhagen
| 4 ans |
David Helgason | M | 46 |
University of Copenhagen
| 4 ans |
Salim Nice | M | - |
Seattle University
| 4 ans |
Haibin Zheng | M | - |
University of Copenhagen
| 3 ans |
Susanne Høiberg | M | - |
University of Copenhagen
| 4 ans |
Charlotte Zarp-Andersson | F | - | - | |
Jørgen Wedel | M | 75 | 12 ans | |
Mette Carlstedt | F | 56 | 18 ans | |
Jørgen Okkels Nielsen | M | 76 | 5 ans | |
Lars Eigen Møller | M | - |
University of Copenhagen
| 5 ans |
Inge Holm Lauritzen | F | 57 | 9 ans | |
Barbara Angela Barak Rimba | F | 47 |
Seattle University
| 4 ans |
Jesper Høiland | M | 63 | 8 ans | |
Else Sissel Vorstrup | M | - | - | |
Peter Hugreffe Ankersen | M | - | - | |
Ching Hui Hsu | F | 50 |
Seattle University
| 4 ans |
Karsten Witt | M | 68 |
University of Copenhagen
| 3 ans |
Rasmus Lund | M | 50 |
University of Copenhagen
| 5 ans |
Stephen Sullivan | M | - |
Seattle University
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Danemark | 86 | 86,00% |
Etats-Unis | 14 | 14,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Maj-Britt Kaltoft
- Réseau Personnel